Point72 Middle East Fze Rigel Pharmaceuticals Inc Transaction History

Point72 Middle East Fze

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.82 $2,951 - $4,795	-2,635 Reduced 19.29%	11,026 $14,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $8,115 - $12,984	6,492 Added 90.56%	13,661 $18,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $11.9 $4,803 - $85,311	7,169 New	7,169 $0

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Point72 Middle East Fze, based on Form 13F filings with the SEC.

Stay updated on Point72 Middle East Fze with notifications on news.